odalasvir + simeprevir + ritonavir

**odalasvir + simeprevir + ritonavir** is an investigational oral combination regimen designed for the treatment of chronic hepatitis C virus (HCV) infection[1][2][3][5][6]. - **Odalasvir** is a HCV NS5A inhibitor, primarily cleared by biliary secretion and showing minimal metabolism. It inhibits viral replication by targeting the NS5A protein, which plays a critical role in viral RNA replication and assembly[1][3]. - **Simeprevir** is a HCV NS3/4A protease inhibitor, acting by blockading the protease necessary for viral polyprotein processing[1][3][4]. - **Ritonavir** is a potent CYP3A inhibitor, here likely used as a pharmacokinetic enhancer to increase plasma concentrations of simeprevir (and possibly odalasvir) by inhibiting their CYP3A-mediated metabolism. This combination is being studied for its ability to deliver potent, multi-targeted antiviral activity allowing for shorter-course HCV therapy. There are drug-drug interaction concerns, particularly with simeprevir and ritonavir (possibly leading to increased simeprevir exposure)[1]. The combination has been evaluated in early phase clinical pharmacology and safety studies primarily sponsored by Janssen[1][5]. No unique brand name or trade name for this specific three-drug regimen has been reported.